Mr. Bill Mitoulas reports

MEDX ANNOUNCES INTENTION TO SEEK ACCEPTANCE FOR AMENDMENT TO WARRANTS

MedX Health Corp. is making an application to the TSX Venture Exchange for acceptance of the proposed amendment to the terms of 17,495,472 share purchase warrants issued in April, May and July, 2020, in connection with private placements completed at that time. Pursuant to acceptance by the TSX-V during 2022, the expiration date of the warrants was extended to Dec. 31, 2023. Subject to and conditional on acceptance by the TSX-V, the company will amend the exercise price of the warrants from 20 cents to 14 cents. Each of the warrants is exercisable to purchase one common share from the treasury of MedX.

About MedX Health Corp.

MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy on DermSecure telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products Siametrics, Simsys and MoleMate, which MedX manufactures in its ISO 13485-certified facility. Siametrics, Simsys and MoleMate include hand-held devices that use patented technology utilizing light and its remittance to view up to two millimetres beneath suspicious moles and lesions in a pain-free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration, and Conformite Europeenne for use in Canada, the United States, Australia, New Zealand, the European Union, Brazil and Turkey.

We seek Safe Harbor.